UPDATE: March 10, 2026 – The dispute between Novo Nordisk (“Novo”) and Hims & Hers (“Hims”) appears to have been resolved very quickly. On March 9, the companies announced an agreement allowing Hims to offer FDA-approved Wegovy® and Ozempic®, including the recently released tablets, through its telehealth platform at the same self-pay prices as... READ MORE
GLP-1 Gold Rush Meets Legal Reality: Novo Nordisk Challenges Compounded Alternatives
Posted on March 5, 2026 in Health Law News
Published by: Hall Render
